指南与共识中毒与环境急症

临床毒理学推荐协作组关于急性口服过量中毒时活性炭给药的推荐意见

Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose.
指南 / 共识 · Clin Toxicol (Phila) · 2026-03-30
一句话结论国际临床毒理学学会工作组基于系统评价与改良德尔菲法,推荐对多种特定毒物在个体化风险评估下可超过传统1小时时间窗给予活性炭,并明确不推荐用于砷、铁、锂、二甲双胍等中毒。

临床毒理学推荐协作组下属活性炭工作组基于系统评价纳入43种毒物或毒物类别,采用RAND/UCLA适宜性方法定义的 disagreement index 衡量共识强度,经两轮改良德尔菲法形成推荐。工作组认为活性炭对砷、铯、铜、乙醇、甲醇、乙二醇、铁、铅、锂和二甲双胍中毒无作用,而对多种抗心律失常药、β受体阻滞剂、钙通道阻滞剂、卡马西平、地高辛、对乙酰氨基酚、水杨酸盐、三环类抗抑郁药等中毒是适当的。对多种毒物在个体化风险评估下可超过摄入后6小时给予活性炭,若怀疑持续吸收还可延长;对卡马西平、地高辛、秋水仙碱、氨苯砜、苯巴比妥、苯妥英、铊和茶碱中毒可考虑多剂量活性炭增强清除。作者强调不应仅为给予活性炭而气管插管。

要点

  • 活性炭对砷、铯、铜、乙醇、甲醇、乙二醇、铁、铅、锂和二甲双胍中毒无作用。
  • 对多种特定毒物(如对乙酰氨基酚、水杨酸盐、卡马西平、苯巴比妥、茶碱、三环类抗抑郁药等)活性炭是适当的;对卡马西平、对乙酰氨基酚、百草枯、苯巴比妥、水杨酸盐、铊、茶碱、丙戊酸和维拉帕米中毒,可追加一剂活性炭以完成胃肠道去污。
  • 根据个体化风险评估,对许多毒物活性炭在摄入后6小时内是适当的;若怀疑持续吸收(如药物团块形成、某些缓释制剂或药物负荷超过溶解度极限),可在摄入6小时后给予活性炭用于胃肠道去污。
  • 多剂量活性炭用于增强清除,对卡马西平、强心苷、秋水仙碱、氨苯砜、苯巴比妥、苯妥英、铊和茶碱中毒是适当的。
  • 不应仅为给予活性炭而对预计不会出现临床显著中毒并发症的患者行气管插管;对已有气管插管临床指征者(如气道受损或无法保护、呼吸衰竭、意识显著下降、难治性癫痫、血流动力学不稳定),置入鼻胃管或口胃管以助活性炭胃肠道去污是合理的。

适用人群与场景

  • 急性口服过量中毒患者,涉及工作组评估的43种毒物或毒物类别。
  • 适用于急诊及中毒救治场景,具体毒物名单见管理栏。
  • 对预计不会出现临床显著中毒并发症的患者,不应仅为给予活性炭而行气管插管。

诊断标准与关键阈值

  • 根据个体化风险评估,对许多毒物活性炭在摄入后6小时内是适当的;若怀疑持续吸收(如药物团块形成、某些缓释制剂或药物负荷超过溶解度极限),可在摄入6小时后给予活性炭用于胃肠道去污。
  • 不同毒物和不同制剂的推荐最大摄入后时间不同。

处置流程与药物剂量

  • 活性炭无作用的毒物:砷、铯、铜、乙醇、甲醇、乙二醇、铁、铅、锂和二甲双胍。
  • 活性炭适当的毒物:抗心律失常药(I型和III型未具体讨论)、β肾上腺素能拮抗剂、安非他酮、钙通道阻滞剂、卡马西平、强心苷、氯喹、可卡因、秋水仙碱、氰化物、氨苯砜、苯海拉明、丙吡胺、Xa因子抑制剂、布洛芬、异烟肼、拉莫三嗪、甲氨蝶呤、吗氯贝胺、阿片类、有机磷杀虫剂、对乙酰氨基酚、百草枯、苯巴比妥、苯妥英、奎尼丁和奎宁、水杨酸盐、选择性5-羟色胺再摄取抑制剂、磺脲类、铊、茶碱、三环类抗抑郁药、丙戊酸、文拉法辛和华法林。
  • 追加一剂活性炭以完成胃肠道去污:卡马西平、对乙酰氨基酚、百草枯、苯巴比妥、水杨酸盐、铊、茶碱、丙戊酸和维拉帕米中毒后。
  • 多剂量活性炭增强清除:卡马西平、强心苷、秋水仙碱、氨苯砜、苯巴比妥、苯妥英、铊和茶碱中毒。
  • 对已有气管插管临床指征者(如气道受损或无法保护、呼吸衰竭、意识显著下降、难治性癫痫、血流动力学不稳定),置入鼻胃管或口胃管以助活性炭胃肠道去污是合理的。
  • 对存在发生危及生命毒性临床显著风险的患者,气管插管以安全助胃肠道去污是合理的,尤其当其他治疗选择不存在或不可用时。
  • 不应仅为给予活性炭而对无气管插管指征的患者行鼻胃管或口胃管置入。

红旗征与不能漏的情况

  • 气管插管并非良性操作,与多种不良事件高发生率相关,如新发血流动力学不稳定、严重低氧血症和心脏骤停,这些在儿童中似乎更常见。
  • 在超过2200例中毒患者的三项研究中,气管插管后低血压发生率1.5%至11.8%,血氧饱和度下降3.4%至7.1%,心脏骤停0.4%。
  • 气管插管后给予活性炭的误吸风险报告为低(1-4%)。

研究设计与关键结果

  • 工作组基于系统评价纳入43种毒物或毒物类别,采用预设格式起草投票声明,以RAND/UCLA适宜性方法定义的不一致指数衡量共识强度,经两轮改良德尔菲法达成专家共识。
  • 工作组结论:活性炭对砷、铯、铜、乙醇、甲醇、乙二醇、铁、铅、锂和二甲双胍中毒无作用。
  • 活性炭对多种特定毒物中毒是适当的;对部分毒物可追加一剂以完成胃肠道去污;对部分毒物可考虑多剂量活性炭增强清除。
  • 根据个体化风险评估,对许多毒物活性炭在摄入后6小时内是适当的;若怀疑持续吸收,可在6小时后给予。

证据类型、等级与局限

  • 证据类型:基于系统评价的指南推荐,采用改良德尔菲法达成专家共识。
  • 现有证据水平主要为低或极低质量,但临床决策仍属必要。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对砷、铁、锂、二甲双胍等中毒不应使用活性炭去污。
  • 对多种特定毒物中毒,可根据个体化风险评估在摄入6小时后仍给予活性炭;怀疑持续吸收时可延长。
  • 对卡马西平、对乙酰氨基酚、百草枯、苯巴比妥、水杨酸盐、铊、茶碱、丙戊酸和维拉帕米中毒,可追加一剂活性炭以完成胃肠道去污。
  • 对卡马西平、强心苷、秋水仙碱、氨苯砜、苯巴比妥、苯妥英、铊和茶碱中毒,可考虑多剂量活性炭增强清除。
  • 不应仅为给予活性炭而行气管插管;对已有气管插管指征者,置入鼻胃管或口胃管以助活性炭给药是合理的。
  • 决定气管插管以助活性炭给药前,需权衡操作并发症与预期可预防的毒性;此决策困难时,可求助当地中毒中心或床旁毒理学会诊。
  • 若因其他指征(如需血液透析或体外循环,或转院)已行气管插管,则风险-获益改变,有利于给予活性炭。

指南或共识出处

  • 临床毒理学推荐协作组(Clinical Toxicology Recommendations Collaborative)关于急性口服过量中毒时活性炭给药的推荐意见,发表于 Clinical Toxicology (Phila)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The Clinical Toxicology Recommendations Collaborative was established by three international clinical toxicology societies and tasked to produce recommendations on the management of poisonings. The Activated Charcoal in Clinical Toxicology Workgroup (the Workgroup) was formed to provide recommendations on the administration of activated charcoal for gastrointestinal decontamination and enhanced elimination in poisoning.

METHODS: Based on a systematic review of the literature, 43 poisons or poison categories were selected for appraisal. Voting statements were drafted using a predetermined format. Strength of consensus was measured using the Disagreement Index as defined by the RAND/University of California at Los Angeles Appropriateness Method. A two-round modified Delphi method was used to reach expert consensus.

RESULTS: The Workgroup concluded that there is no role for activated charcoal in poisoning from arsenic, caesium, copper, ethanol, methanol, ethylene glycol, iron, lead, lithium, and metformin. Activated charcoal is appropriate after ingestion of antidysrhythmics (types I and III not discussed specifically), beta-adrenergic antagonists, bupropion, calcium-channel blockers, carbamazepine, cardiac glycosides, chloroquine, cocaine, colchicine, cyanide, dapsone, diphenhydramine, disopyramide, factor Xa inhibitors, ibuprofen, isoniazid, lamotrigine, methotrexate, moclobemide, opioids, organophosphorus insecticides, paracetamol (acetaminophen), paraquat, phenobarbital, phenytoin, quinidine and quinine, salicylates, selective serotonin reuptake inhibitors, sulfonylureas, thallium, theophylline, tricyclic antidepressants, valproic acid, venlafaxine, and warfarin. An additional dose of activated charcoal to complete gastrointestinal decontamination is appropriate after ingestion of carbamazepine, paracetamol, paraquat, phenobarbital, salicylates, thallium, theophylline, valproic acid and verapamil. The maximum time post-ingestion for which activated charcoal administration is recommended differs for each poison and different formulations. According to an individualized risk assessment, activated charcoal is appropriate up to 6 h post-ingestion for many poisons. If ongoing absorption is suspected, which may occur, for example, with pharmacobezoar formation, certain modified-release preparations, or when drug burden exceeds the limits of solubility, then activated charcoal can be administered beyond 6 h post-ingestion for gastrointestinal decontamination. Multiple-dose activated charcoal for enhanced elimination is appropriate in poisoning with carbamazepine, cardiac glycosides, colchicine, dapsone, phenobarbital, phenytoin, thallium and theophylline.

UNLABELLED: Before deciding to perform endotracheal intubation to assist with the administration of activated charcoal, every clinician needs to weigh the potential complications and adverse effects of this procedure against the toxicity expected to be prevented by the administration of activated charcoal. This is a challenging decision, and a local poison centre and/or a bedside toxicology consultation can assist with this decision. Endotracheal intubation is not a benign procedure and is associated with a high rate of various adverse events, such as new haemodynamic instability, severe hypoxaemia, and cardiac arrest, which seem more common in children. In three studies that evaluated the risks of endotracheal intubation in over 2,200 poisoned patients, the rates of hypotension were between 1.5% and 11.8%, desaturation between 3.4% and 7.1%, and cardiac arrest in 0.4%. The risk of aspiration following administration of activated charcoal after endotracheal intubation is reported to be low (1-4%). Therefore, the decision to endotracheally intubate a patient to administer activated charcoal needs to carefully assess the patient's other comorbidities and the expected toxicity of the ingestion, which needs to be clinically significant to outweigh the risk of endotracheal intubation. Endotracheal intubation may also be considered if another treatment, such as haemodialysis or extracorporeal circulation, might be required or for transportation to another institution for ongoing clinical care. In these situations, for which endotracheal intubation has been performed for another indication, the risk-benefit will change in favour of activated charcoal administration. The following good practice statements were adopted to address the use of endotracheal intubation to facilitate the administration of activated charcoal. Endotracheal intubation should not be performed solely for the purpose of administration of activated charcoal in patients not anticipated to develop clinically significant complications of poisoning.In patients in whom endotracheal intubation is clinically indicated (e.g., compromised or unprotected airway, respiratory failure, significantly diminished level of consciousness, refractory seizures, hemodynamic instability), insertion of a nasogastric or orogastric tube is reasonable to facilitate gastrointestinal decontamination with activated charcoal.In patients with a clinically significant risk of developing life-threatening toxicity, endotracheal intubation is reasonable to safely facilitate gastrointestinal decontamination, especially if other treatment options are nonexistent or unavailable.Use of nasogastric or orogastric tube insertion without endotracheal intubation to facilitate the administration of activated charcoal: The following good practice statement was adopted: Nasogastric or orogastric tube insertion without endotracheal intubation should not be performed solely for the purpose of administration of AC.

DISCUSSION: The decision to use activated charcoal is complex and depends primarily on the nature of the poison(s), the time since ingestion, the severity of the symptoms present at the time of decision or expected based on the dose ingested or patient comorbidities, and the availability of antidotes or other treatments. Although the existing level of evidence is primarily of low or very low quality, clinical decisions are still necessary.

CONCLUSIONS: The Workgroup recommends the administration of a single-dose of activated charcoal beyond the traditional 1 h post-ingestion time point in selected poisons and introduces the concept of an additional dose of activated charcoal to prevent further absorption of poisons that may remain in the gastrointestinal tract for prolonged periods of time. Multiple-dose activated charcoal is also recommended to enhance elimination in selected clinical scenarios.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Hoegberg LCG, Gosselin S, Buckley NA, et al. Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose. Clin Toxicol (Phila). 2026. PMID: 41906697. doi:10.1080/15563650.2025.2609807

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。